Częstość występowania mutacji somatycznych RAS w raku rdzeniastym tarczycy — analiza populacji polskiej by Oczko-Wojciechowska, Malgorzata et al.
121
Prace oryginalne/original PaPers
Endokrynologia Polska
DOI: 10.5603/EP.2015.0018
Tom/Volume 66; Numer/Number 2/2015
ISSN 0423–104X
Małgorzata Oczko-Wojciechowska M.D., Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial 
Cancer Centre and Institute of Oncology in Warsaw, Gliwice Branch, Wybrzeże Ak 15, 44–101 Gliwice, tel.: +48 32 278 97 20,  
e-mail: gosiaoczko@io.gliwice.pl

The prevalence of somatic RAS mutations in medullary 
thyroid cancer — a Polish population study
Częstość występowania mutacji somatycznych RAS w raku rdzeniastym tarczycy 
— analiza populacji polskiej
Małgorzata Oczko-Wojciechowska1, Aleksandra Pfeifer1, 4, Dagmara Rusinek1, Agnieszka Pawlaczek1, 
Jadwiga Żebracka-Gala1, Małgorzata Kowalska1, Monika Kowal1, Michał Świerniak1, 5,  
Jolanta Krajewska1, Tomasz Gawlik1, Ewa Chmielik3, Agnieszka Czarniecka3,  
Sylwia Szpak-Ulczok1, Barbara Jarząb1
1Nuclear Medicine and Endocrine Oncology Department, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of 
Oncology, Gliwice Branch, Poland 
2Department of Tumour Pathology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, 
Poland 
3Clinic of Oncology and Reconstructive Surgery Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, 
Gliwice Branch, Poland  
4Faculty of Automatic Control, Electronics and Computer Science, Silesian University of Technology, Gliwice, Poland 
5Genomic Medicine, Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Poland
Abstract
Introduction: Somatic RET mutations are detectable in two-thirds of sporadic cases of medullary thyroid cancer (MTC). Recent studies 
reported a high proportion of RAS somatic mutations in RET negative tumours, which may indicate RAS mutation as a possible alterna-
tive genetic event in sporadic MTC tumorigenesis. Thus, the aim of the study was to evaluate the frequency of somatic RAS mutations 
in sporadic medullary thyroid cancer in the Polish population and to relate the obtained data to the presence of somatic RET mutations.
Material and methods: Somatic mutations (RET, RAS genes) were evaluated in 78 snap-frozen MTC samples (57 sporadic and 21 heredi-
tary) by direct sequencing. Next, three randomly selected RET-negative MTC samples were analysed by the next generation sequencing. 
Results: RAS mutation was detected in 26.5% of 49 sporadic MTC tumours. None of all the analysed samples showed N-RAS mutation. 
When only RET-negative samples were considered, the prevalence of RAS mutation was 68.7%, compared to 6% observed in RET-positive 
samples. Most of these mutations were located in H-RAS codon 61 (72%). None of 21 hereditary MTC samples showed any RAS mutations. 
Conclusions: RAS mutations constitute a frequent molecular event in RET-negative sporadic medullary thyroid carcinoma in Polish 
patients. However, their role in MTC tumorigenesis remains unclear. (Endokrynol Pol 2015; 66 (2): 121–125)
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Streszczenie
Wstęp: Somatyczne mutacje proto-onkogenu RET wykrywane są w trzech czwartych wszystkich sporadycznych raków rdzeniastych 
tarczycy (MTC). Ostatnie badania wykazały, że mutacja genu RAS jest również częstym wydarzeniem w sporadycznych guzach MTC, co 
może oznaczać, że mutacje genów z rodziny RAS są alternatywnym wydarzeniem molekularnym w kancerogezie sporadycznej postaci 
tego raka.
Z tego względu celem niniejszej pracy było oszacowanie częstości występowania mutacji genów RAS w sporadycznym raku rdzeniastym 
tarczycy w populacji polskiej i odniesieniu częstości ich występowania do obecności mutacji somatycznych proto-onkogenu RET.
Materiał i metody: Materiał do badań stanowiło 78 fragmentów guza raka rdzeniastego tarczycy (57 próbek postaci sporadycznej i 21 
dziedzicznej MTC). Analizowano mutacje genu RET, H-RAS, K-RAS i N-RAS metodą bezpośredniego sekwencjonowania a także 3 próbki 
raka sporadycznego, wybrane losowo, zostały zeskwencjonowane metodą głębokiego sekwencjonowania (Illumina).
Wyniki: Mutację genów RAS wykryto w 26,5% z 49 przeanalizowanych guzów sporadycznej postaci MTC. Natomiast, gdy tylko brano 
pod uwagę próbki RET-negatywne, częstość występowania mutacji genów RAS wynosiła 68,7% w porównaniu z 6% obserwowanych 
w guzach RET-pozytywnych. Nie wykryto, w żadnej z próbek, mutacji genu N-RAS. Najczęściej wykrywaną mutacją była zmiana 
w kodonie 61 genu H-RAS (72%). Nie wykryto mutacji genów RAS w żadnej z próbek dziedzicznego guza raka tarczycy.
Wnioski: Mutacje somatyczne genów RAS są częstym wydarzeniem obserwowanym w RET-negatywnych sporadycznych rakach 
rdzeniastych tarczycy w populacji polskiej. Jednakże rola tych mutacji w rozwoju rdzeniastego raka tarczycy nie jest do końca poznana. 
(Endokrynol Pol 2015; 66 (2): 121–125)
Słowa kluczowe: rak rdzeniasty tarczycy; RET; RAS; mutacja inicjujaca
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Introduction
Medullary thyroid cancer (MTC) arises from calcitonin 
secreting parafollicular C cells of thyroid and accounts 
for 3–5% of all thyroid cancers [1–3]. The disease in 
ultrasound imaging does not differ from other type of 
tumour [4]. Medullary thyroid cancer (MTC) occurs as 
both hereditary and sporadic form. The hereditary type 
of MTC is secondary to the RET (Rearranged during 
Transfection) proto-oncogene germline mutations that 
are associated with multiple endocrine neoplasia type 2 
(MEN2a, MEN2b) and familial medullary thyroid 
cancer (FMTC). 
The RET gene is located on chromosome 10q 11.2, 
contains 21 exons, and encodes a receptor tyrosine 
kinase, which is a transmembrane protein comprising 
of extracellular, transmembrane, and intracellular (cy-
toplasmic) domains. The RET gene plays an important 
role during morphogenesis and is normally activated 
by the ligand belonging to glial cell-derived neurotropic 
factor (GDNF) family and co-receptor GFRa. Mutations 
of the RET proto-oncogene lead to its autophosphoryla-
tion and to a gain of function resulting in constitutive 
activation of RET receptor [5–7]. 
The global risk of the detection of a germinal RET 
mutation in the Polish MTC population is about 
10%, even if there is no positive family history 
and no features of MEN2a syndrome are present 
[8]. Simultaneously, the risk of MTC development 
in RET germline mutation carriers is nearly 100%. 
Therefore, molecular diagnostics is obligatory in all 
MTC subjects. These germline mutations concern the 
following RET gene exons 5, 8, 10, 11, 13, 14, 15, and 
16. A germline mutation with a higher transforming 
activity, located in RET exon 16 (M918T), results in 
MEN2b syndrome (medullary thyroid cancer, pheo-
chromocytoma, and typical phenotype features). The 
most characteristic mutation for MEN2a syndrome, 
located in RET exon 11 (codon 634), also related with 
the highest probability of pheochromocytoma and 
parathyroid hyperplasia, is observed in up to 20% 
of MEN2a subjects [9, 10].
Somatic RET mutations are also detectable in two-
thirds of sporadic MTC cases. Alteration in RET exon 16 
(M918T) is the most frequent one, accounting for nearly 
80% of all detected RET somatic mutations. It is associ-
ated with more aggressive course of the disease [11–13]. 
Recent studies suggest a high proportion of RAS somatic 
mutations in RET-negative tumours [14–16]. Thus, RAS 
gene mutations could be considered as an alternative 
genetic event in sporadic MTC tumorigenesis. These 
mutations are present in three RAS proteins: K-RAS, 
H-RAS, and N-RAS — small GTPases that play a role in 
cellular growth, differentiation, adhesion, and migra-
tion. Normally, RAS is activated by external signals from 
tyrosine kinases receptor (Fig. 1). Mutations of this gene 
lead to constitutive activation of the RAS protein. Most 
RAS mutations are limited to hot spot codons located in 
exons 2 and 3. A mutation in exon 3 of N-RAS (codon 61) 
is the most frequent in poorly differentiated thyroid 
cancers [17, 18] (Fig. 1). 
The aim of our study was to evaluate the frequency 
of somatic RAS mutations in sporadic medullary thy-
roid cancer in the Polish population and to relate the 
obtained data to the somatic RET mutations. 
Material and methods
Samples
Seventy-eight MTC samples were analysed (57 sporadic 
and 21 hereditary). Tumour samples were collected 
from the biobank of the Department of Nuclear Medi-
cine and Endocrine Oncology in M. Sklodowska-Curie 
Memorial Cancer Centre and Institute of Oncology, 
Gliwice Branch. RET mutation status was evaluated 
in all 57 sporadic MTC tumour samples, whereas RAS 
mutation status was assessed in 49/57 sporadic MTC 
samples and in all 21 hereditary MTC tumours. 
RET and RAS analysis method
DNA for RET germline mutations was extracted from 
peripheral blood by the desalting method and Genomic 
Maxi AX Kit (A&A Biotechnology). Mutation screening 
was performed according to a standard algorithm ap-
proved by the American and European MTC Manage-
ment Guidelines [9, 10], which assumes analysis of exons 
Figure 1. MAP Kinase signalling pathway. RTK — receptor 
tyrosine kinase
Rycina 1. Ścieżka sygnałowa MAPK. RTK — receptor kinazy 
tyrozynowej
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10, 11, 13, 14, 15, and 16. These exons were sequenced 
directly using Big Dye 1.1 reagent and a 3130xl Genome 
Analyser (Life Technologies). For RET and RAS somatic 
mutations, DNA was extracted from snap-frozen tissue 
samples by the DNeasy Blood and Tissue Kit (Qiagen). 
Twenty-one exons of the RET gene and exon 2 and 3 of 
H-RAS, K-RAS, and N-RAS (codons 12, 13, and 61) were 
sequenced directly as described above.
Deep sequencing
Next generation sequencing of RNA was performed 
in three randomly selected RET-negative MTC sam-
ples using TruSeq Sample Preparation Kit (Illumina) 
and TruSeq SR Cluster Kit (Illumina) according to the 
manufacturer’s protocol. Single-end 76 bp sequencing 
on Genome Analyzer IIx (Illumina) was carried out. 
Low quality reads were filtered out with FASTX_Toolkit 
0.0.13. Next, good quality reads were aligned to the hu-
man genome hg19 using TopHat 2.0.11 [19]. Duplicate 
reads were removed with PicardTools 1–56. Variants 
(single nucleotide variants, small insertions, and dele-
tions) were identified using VarScan 2.3.6 [20]. The an-
notation of variants was performed with Annovar [21]. 
Results 
Somatic RET mutational screening  
in sporadic MTC
Among 57 sporadic MTC samples somatic RET point 
mutations were found in 33 cases (57.8%). The most 
frequent RET mutation was localised in codon M918T, 
16/33 (48.5%). The other RET mutations were detected 
in codon C634, 6/33 (18%), codon C 630, 2/33 (6%), 
and one in codon C618S (3%), codon A883F (3%), and 
H568N (3%). Deletions of 6 to 9 nucleotides in RET 
exon 11 were found in 4 sporadic MTC tumours and 
one deletion with insertion in exon 11. Detailed results 
are presented in Table I.
Somatic RAS mutational screening  
in sporadic MTC
The status of three RAS genes was investigated in 
28 somatic RET-positive MTC samples and 16 somatic 
RET-negative samples. A RAS mutation was found in 2/33 
of sporadic MTC samples with RET somatic mutation 
(6%) and in 11/16 (68.8%) of RET negative MTC tumours. 
Among sporadic RET-positive samples, one tumour 
harboured H-RAS codon 61 mutation, whereas K-RAS 
codon 13 mutation was found in the second sample. 
Among RET-negative samples, 8 H-RAS mutations were 
detected and 3 K-RAS. The details are reported in Table II.
Table I. Somatic RET mutations were analysed in all 57 
sporadic MTC tumours. The most frequent one was RET 
M918T mutation, comprising nearly 50% of all RET-positive 
sporadic MTC samples
Tabela I. Mutacje somatyczne proto-onkogenu RET oznaczono 
we wszystkich 57 próbkach sporadycznego MTC. Najczęściej 
wykrywaną mutacją, stanowiącą prawie 50% wszystkich 
RET-dodatnich próbek, była mutacja M918T
Number of samples Type of RET mutation Exon
16 M918T (Met>Thr) 16
1 A883F (Ala>Phe) 15
5 C634R (Cys>Arg) 11
1 C634W (Cys>Trp) 11
1 C630R (Cys>Arg) 11
1 C630G (Gys>Gly) 11
1 C618S (Cys>Ser) 1
1 H568N (His>Asn) 8
2 Del 7 bp 11
1 Del 6 bp 11
1 Del 19 bp 11
2 Del/ins 11
Total: 33 (57.9%)
Table II. The presence of RAS mutation was evaluated in 49 sporadic MTC samples (33 RET-positive and 16 RET-negative). 
RAS mutation was detected in 11/16 RET-negative tumours and in 2/33 RET-positive samples
Tabela II. Status mutacji RAS oceniono w 49 próbkach sporadycznego MTC (33 RET-dodatnich i 16 RET-ujemnych). Mutacje 
RAS wykryto w 11/16 RET –ujemnych guzach i w 2/33 RET-dodatnich próbkach 
Number of samples with a particular mutation H-RAS mutations K-RAS mutations RET mutations
4 Q61K (Gln>Lys) Negative
4 Q61R (Gln>Arg) Negative
2 G12R (Gly>Arg) Negative
1 Q61R (Gln>Arg) Negative
1 Q61R (Gln>Arg) H568N
1 G13S (Gly>Ser) M918T
Total: 13 (26.5%)
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None of 21 hereditary MTC samples showed any 
RAS mutations. Moreover, none of all analysed samples 
(21 germline RET-positive, 28 somatic RET-positive, 
and 16 somatic and germline RET-negative samples) 
showed N-RAS mutation.
Next generation sequencing
The NGS was performed in three randomly selected 
RET-negative MTC samples. In RNA-seq, 22 million 
good quality reads were obtained for MTC10, 24 mil-
lion for MTC20, and 28 million for MTC22 to detect 
single nucleotide variants, insertions, and deletions. 
Among identified variants, two mutations were present 
in HRAS exon 3 in two distinct MTC samples. They 
were p.Q61K (c.C181A) HRAS mutation in MTC20 and 
p.Q61R (c.A182G) HRAS mutation in MTC22. No other 
putative driver mutations were found. 
Discussion
Somatic mutations of three RAS genes have been re-
ported with reference to several tumours [22], among 
them differentiated thyroid cancer [23–25]. From the 
clinical point of view, screening for RAS mutations is 
important in patients with colorectal carcinoma where 
the presence of K-RAS mutation is associated with poor 
response to anti-EGFR therapies [26–28]. However, 
in differentiated thyroid cancer, the detection of RAS 
mutation has not thus far determined any treatment 
decision. Interestingly, all mutations that play role in 
thyroid cancer despite its origin (follicular or parafol-
licular cells) are involved in MAPK kinase pathway.
The prevalence of RET somatic mutations (57,8%) in 
our analysed group is consistent with previous reports 
[15, 29–31], where the frequency of somatic RET muta-
tion ranges between 38% [29] and 71% [15]. Moreover, 
similarly to other data [29, 30], the most frequent so-
matic RET mutation in our group was M918T, which 
constituted nearly 50% of all RET somatic mutations. 
However, other somatic mutations in exons 10–11 were 
also found in our material.
In the present study, a mutational analysis of H-
RAS, K-RAS, and N-RAS in a series of 65 MTC samples 
(49 sporadic and 21 hereditary), representative for the 
Polish population, was performed. RAS mutation was 
detected in 26.5% of all sporadic MTC tumours, but 
when only RET-negative samples were considered, the 
prevalence of RAS mutation was 68.7%. A higher pro-
portion of H-RAS mutation that constituted 72% of all 
detected RAS mutations was observed, which is consist-
ent with all reported results [15, 16, 32] and comparable 
with studies published by Moura et al. and Boichard 
et al. that reported RAS mutations present in 68% and 
81% of RET-negative sporadic MTC samples, respec-
tively [14, 16]. The results of different analyses of RAS 
mutations in MTC are controversial with reference to 
their different frequency reported by different studies. 
Ciampi et al. suggest that RAS mutations are extremely 
rare in MTC and stand for ~11% of all sporadic MTC 
cases and 17.6% when only RET-negative MTC samples 
were evaluated [33]. Schlumberger also reported such 
a low prevalence of RAS mutation in MTC, only in 8% 
of all sporadic MTC 34. Some studies did not show any 
RAS mutation in MTC [35] or confirmed its very low 
frequency, like in the Shulten et al. study [36], where 
the only one sample among 15 MTC tumours analysed 
demonstrated RAS mutation, while in our study RAS 
mutation was diagnosed in 26.5% of all cases. 
The reason of variability in the prevalence of RAS 
mutations in MTC is unknown. One explanation could 
be related to differences between analysed populations. 
However, when we look at Italian results only, some 
differences may also be noticed. Ciampi et al. reported 
a very low prevalence of RAS mutation in RET-negative 
sporadic MTC (17.6%) [32] while in the Scarpa and 
Fugazzola group the frequency of RAS mutation was 
57% [31]. This percentage was even higher in our group 
— 68.7 % of RET-negative tumours showed RAS muta-
tion. However, of note, the Elisei group involved the 
largest series of analysed MTC samples from different 
Italian centres [32]. The second explanation could be 
the different methodologies used for mutational RAS 
screening and their sensitivity. This is also visible in 
the Italian results, where Ciampi et al. used PCR and 
direct sequencing [32], while Simbolo et al. applied 
next generation sequencing [31]. Nonetheless, these 
differences do not explain all discrepancies because 
PCR and direct sequencing were used in many studies. 
The third explanation is related to the material used for 
analysis. Some studies comparing the results achieved 
from formalin-fixed paraffin-embedded (FFPE) samples 
and frozen tissues demonstrated a higher rate of RAS 
mutations in snap-frozen tissues than in FFPE samples 
[37]. Another important issue related to FFPE samples 
is the poor quality of the material leading to false-
negative results [38]. This could explain the low rate of 
RAS mutation in the Schlumberger et al. and Rapa et 
al. studies as both groups used FFPE samples for RAS 
mutational screening, contrary to data from Ciampi et 
al. performed on snap-frozen samples [32, 34, 35]. We 
underline that we also used snap-frozen MTC samples.
Interestingly, in our set of RET-positive sporadic 
MTC samples, RAS mutations were also found (6%). 
Until now RET and RAS mutations were reported as 
mutually exclusive [15, 16, 32], and only in one study 
was RAS mutation detected in RET-positive MTC [14]. 
The coexistence of two oncogenic mutations is rare. In 
some papillary thyroid cancer cases RET rearrange-
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ments coexist with B-RAF or RAS mutation [39–41] or 
BRAF and K-RAS mutations [42]. A similar situation 
is observed in lung adenocarcinoma, where PIK3CA 
mutations are accompanied by with K-RAS or EGFR 
mutations [43, 44]. These data may suggest that RAS 
could be a secondary event, not a driver mutation. How-
ever, to date there is no published transforming assays 
demonstrating that RAS mutations play an important 
role in MTC tumorigenesis. 
Summary
The analysis of three RAS genes (H-RAS, K-RAS, N-
RAS) revealed that 29% of sporadic MTCs harbour RAS 
mutations. This rate was much higher when only RET-
negative sporadic MTC were analysed — 69%. Most of 
these mutations were located in H-RAS codon 61 (72%). 
3% of RAS mutations were detected in RET-positive 
sporadic MTC. No N-RAS-positive samples were found. 
The prevalence of RET somatic mutations in the Pol-
ish population is high and is observed in nearly 58% of 
all sporadic MTC tumours. Among them, M918T RET 
mutations constitute 50%.
Conclusions
RAS mutations constitute a frequent molecular event 
in RET-negative sporadic medullary thyroid carcinoma 
in Polish patients. However, their role in MTC tumori-
genesis remains unclear.
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